Seven Fleet Capital Management LP Buys New Shares in Taysha Gene Therapies, Inc. $TSHA

Seven Fleet Capital Management LP bought a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 167,223 shares of the company’s stock, valued at approximately $920,000. Taysha Gene Therapies accounts for 0.7% of Seven Fleet Capital Management LP’s holdings, making the stock its 26th biggest holding. Seven Fleet Capital Management LP owned about 0.06% of Taysha Gene Therapies as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in TSHA. AQR Capital Management LLC increased its stake in shares of Taysha Gene Therapies by 325.6% during the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after acquiring an additional 82,545 shares during the last quarter. Rhumbline Advisers boosted its holdings in Taysha Gene Therapies by 13.5% in the second quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock valued at $539,000 after acquiring an additional 27,794 shares during the last quarter. Prudential Financial Inc. lifted its stake in shares of Taysha Gene Therapies by 50.5% in the 2nd quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock valued at $53,000 after purchasing an additional 7,650 shares in the last quarter. Invesco Ltd. lifted its position in Taysha Gene Therapies by 27.4% during the second quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock valued at $470,000 after buying an additional 43,772 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Taysha Gene Therapies during the 2nd quarter worth $184,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider directly owned 1,136,410 shares in the company, valued at $5,068,388.60. This trade represents a 14.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

TSHA has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Chardan Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Needham & Company LLC lifted their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of “Buy” and an average price target of $11.64.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $6.42 on Friday. The company has a market cap of $1.84 billion, a P/E ratio of -16.89 and a beta of 1.19. The stock has a fifty day moving average price of $5.90 and a 200 day moving average price of $5.22. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. Taysha Gene Therapies, Inc. has a 12 month low of $2.25 and a 12 month high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, research analysts forecast that Taysha Gene Therapies, Inc. will post -0.5 earnings per share for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.